Biomarker-driven strategy for early discontinuation of empirical antifungal treatment in critically ill patients: the role of (1-3)-β- D- glucan using Wako® test

Journal of Antimicrobial Chemotherapy 2026

View at publisher
Authors: Marta Albanell‐Fernández, Montserrat Tuset, A Vergara, M Villanueva, M Barrantes-González, M Bodro, Àlex Soriano, Marta Hernández-Meneses, G Muñoz-Rojas, S Herrera
DOI: 10.1093/jac/dkag226
Cited by: 1
References: 30

Abstract

BACKGROUND: (1,3)-β-D-Glucan (BDG) testing with Fungitell® assay has been shown to support antifungal stewardship by shortening empirical antifungal therapy in critically ill patients; however, data on Wako® assay are lacking. METHODS: Prospective, non-randomized study conducted over 15 months in a tertiary care hospital. Critically ill patients receiving empirical echinocandin therapy with a BDG measurement within 48 h were included. Patients were stratified by Candida score (low risk

Fields of Study & Subjects

Antifungal resistance and susceptibility Antimicrobial Resistance in Staphylococcus Sepsis Diagnosis and Treatment

Publication details

Journal / source
Journal of Antimicrobial Chemotherapy
Publisher
Oxford University Press (OUP)
Volume
81
Issue
8
Publication date
2 July 2026
Language
EN